ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: SA-PO081

Establishment of a Tubule-Specific Renal Panel in AKI

Session Information

Category: Acute Kidney Injury

  • 003 AKI: Clinical and Translational


  • Portz, Brent J, Danville Regional Medical Center, Danville, Virginia, United States
  • Moore, Michael A., Danville Regional Medical Center, Danville, Virginia, United States

Early recognition to allow prevention of Acute Kidney Injury (AKI) is an ongoing inpatient challenge due to AKI’s high morbidity and mortality. The traditional use of changes in serum creatinine and urinary output only define AKI after it is well established and kidney injury has begun. Better biomarkers of early acute renal injury are needed. Developments in systems biology techniques and advancements of genomic and proteomic technologies have provided an emerging list of novel glomerular and renal tubular cell biomarkers.


A comprehensive literature review was completed utilizing PubMed and MEDLINE databases from inception to January 2017 searching for ‘AKI Biomarkers and Systems Biology’. Validated and Non-Validated novel AKI biomarkers discovered at tubule-specific sites via genomic, proteomic and systems biology techniques were identified. Unique biomarkers at distinct nephron segments were composited in a Tubule-Specific Renal Injury Panel.


Amongst other identified markers, KIM-1 (Proximal Tubule), CNTF (Loop of Henle), bcl-2 (Distal Tubule), and NGAL (Collecting Tubule) suggested the highest potential for clinically applicable AKI biomarkers (Table 1).


The establishment of a tubule-specific renal panel is proposed to provide increased sensitivity/specificity to enable diagnosis earlier in acute renal injury.

Table 1: List of Identified Novel Biomarkers at Segment Specific Sites, organism biomarker identified in and availability of commercially validated assays. Bolded *, denotes highest clinically applicable AKI biomarker at each segment. Literature references listed separately.